search button

Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test

  • Authors:
    • Takumi Ochiai
    • Kazuhiko Nishimura
    • Tomoo Watanabe
    • Masayuki Kitajima
    • Tadasuke Hashiguchi
    • Akinori Nakatani
    • Takashi Marusasa
    • Akira Muraki
    • Isao Nagaoka
    • Shunji Futagawa

  • View Affiliations

  • Published online on: March 1, 2010     https://doi.org/10.3892/etm_00000050
  • Pages: 325-329
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of this study was to determine the effect of the addition of oxaliplatin (l-OHP) or irinotecan (SN-38) to 5-fluorouracil (5-FU) using the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) to establish whether leucovorin plus 5-FU should be administered in combination with l-OHP (FOLFOX) or SN-38 (FOLFIRI) in individualized first-line chemotherapy for the treatment of advanced colorectal cancer (CRC). Specimens of primary tumors were obtained from 24 CRC patients who had received no preoperative chemotherapy. CD-DST was performed, and the inhibition rate (IR) was obtained under multiple incubation conditions. The effects of addition of l-OHP or SN-38 were evaluated for the same area under the concentration curve (AUC) of 5-FU based on linear regression analysis. Approximate expression and correlation coefficients (5-FU vs. 5-FU + l-OHP, 5-FU vs. 5-FU + SN-38; AUC of 5-FU=72 and 5-FU vs. 5-FU + l-OHP, 5-FU vs. 5-FU + SN-38; AUC of 5-FU=144) were y=0.94x+8.53 (R2=0.95, p<0.0004), y=0.77x+26.18 (R2=0.76, p<0.0004) and y=0.91x+10.90 (R2=0.94, p<0.0004), y=0.52x+44.61 (R2=0.60, p<0.0004), respectively. Approximate expression of 5-FU vs. 5-FU + l-OHP almost fit the regression line (y=x+b1). This suggests that addition of l-OHP yields a constant additive effect, independent of the IR of 5-FU. However, approximate expression of 5-FU vs. 5-FU + SN-38 fit the regression line (y=ax+b2, a<1, b2≥b1). This suggests that addition of SN-38 yields a greater additive effect due to the lower IR of 5-FU. These results indicate that FOLFIRI should be selected as the first-line chemotherapy for the treatment of poor responders to 5-FU.
View Figures
View References

Related Articles

Journal Cover

March-April 2010
Volume 1 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Hashiguchi T, Nakatani A, Marusasa T, Muraki A, Nagaoka I, Futagawa S, Futagawa S, et al: Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test . Exp Ther Med 1: 325-329, 2010
APA
Ochiai, T., Nishimura, K., Watanabe, T., Kitajima, M., Hashiguchi, T., Nakatani, A. ... Futagawa, S. (2010). Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test . Experimental and Therapeutic Medicine, 1, 325-329. https://doi.org/10.3892/etm_00000050
MLA
Ochiai, T., Nishimura, K., Watanabe, T., Kitajima, M., Hashiguchi, T., Nakatani, A., Marusasa, T., Muraki, A., Nagaoka, I., Futagawa, S."Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test ". Experimental and Therapeutic Medicine 1.2 (2010): 325-329.
Chicago
Ochiai, T., Nishimura, K., Watanabe, T., Kitajima, M., Hashiguchi, T., Nakatani, A., Marusasa, T., Muraki, A., Nagaoka, I., Futagawa, S."Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test ". Experimental and Therapeutic Medicine 1, no. 2 (2010): 325-329. https://doi.org/10.3892/etm_00000050